{
  "source": "PA-Med-Nec-Strensiq.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2136-9\nProgram Prior Authorization/Medical Necessity\nMedication Strensiq® (asfotase alfa)\nP&T Approval Date 11/2017, 5/2019, 5/2020, 5/2021, 6/2021, 6/2022, 6/2023, 10/2023,\n10/2024\nEffective Date 1/1/2025\n1. Background:\nStrensiq® (asfotase alfa) is a tissue nonspecific alkaline phosphatase indicated for the treatment\nof patients with perinatal/infantile and juvenile-onset hypophosphatasia (HPP).\n2. Coverage Criteriaa:\nA. Initial Therapy\n1. Strensiq will be approved based on all of the following criteria:\na. Diagnosis of perinatal/infantile or juvenile-onset hypophosphatasia based on all of\nthe following:\n(1) One of the following:\na. Onset of clinical signs and symptoms of hypophosphatasia prior to age 18\nyears (e.g., respiratory insufficiency, vitamin B6 responsive seizures,\nhypotonia, failure to thrive, delayed walking, waddling gait, dental\nabnormalities, low trauma fractures)\nb. Radiographic evidence supporting the diagnosis of hypophosphatasia at the\nage of onset prior to age 18 (e.g., craniosynostosis, infantile rickets, non-\ntraumatic fractures)\n-AND-\n(2) One of the following:\na. Both of the following:\ni. Patient has low level activity of serum alkaline phosphatase (ALP)\nevidenced by an ALP level below the age and gender-adjusted normal\nrange\nii. Patient has an elevated level of tissue non-specific alkaline phosphatase\n(TNSALP) substrate (e.g., serum pyridoxal 5’-phosphate [PLP] level,\nserum or urine phosphoethanolamine [PEA] level, urinary inorganic\npyrophosphate [PPi level])\n© 2024 UnitedHealthcare Services, Inc.\n1\n-OR-\nb. Confirmation of tissue-nonspecific alkaline phosphatase (TNSALP) gene\nmutation by ALPL genomic DNA testing*\n-AND-\nb. Prescribed by one of the following:\n(1) Endocrinologist\n(2) A specialist experienced in the treatment of metabolic bone disorders\n-AND-\nc. One of the following:\n(1) Both of the following:\na. Diagnosis of perinatal/infantile-onset hypophosphatasia\nb. ",
    "ogist\n(2) A specialist experienced in the treatment of metabolic bone disorders\n-AND-\nc. One of the following:\n(1) Both of the following:\na. Diagnosis of perinatal/infantile-onset hypophosphatasia\nb. Request does not exceed a maximum supply limit of 9 mg/kg/week\n-OR-\n(2) Both of the following:\na. Diagnosis of juvenile-onset hypophosphatasia\nb. Request does not exceed a maximum supply limit of 6 mg/kg/week\n-AND-\nd. One of the following:\n(1) Patient is prescribed Strensiq 18 mg/0.45 mL, Strensiq 28 mg/0.7 mL, or\nStrensiq 40 mg/mL vials\n-OR-\n(2) Both of the following:\na. Patient is prescribed Strensiq 80 mg/0.8 mL vial\nb. Patient’s weight is greater than or equal to 40 kg\nAuthorization will be issued for 6 months.\n*Results of prior genetic testing can be submitted as confirmation of diagnosis of HPP,\nhowever please note that the provider should confirm coverage status of any new\ngenetic testing under the patient’s UnitedHealthcare plan prior to ordering.\n© 2024 UnitedHealthcare Services, Inc.\n2\nB. Reauthorization\n1. Strensiq will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Strensiq therapy (e.g., improvement in\nclinical symptoms, improvement in Radiographic Global Impression of Change)3,4\n-AND-\nb. Clinically relevant decrease from baseline in tissue non-specific alkaline\nphosphatase (TNSALP) substrate (e.g., serum pyridoxal 5’-phosphate [PLP] level,\nserum or urine phosphoethanolamine [PEA] level, urinary inorganic pyrophosphate\n[PPi level])\n-AND-\nc. Prescribed by one of the following:\n(1) Endocrinologist\n(2) A specialist experienced in the treatment of metabolic bone diseases\n-AND-\nd. One of the following:\n(1) Both of the following:\na. Diagnosis of perinatal/infantile-onset hypophosphatasia\nb. Request does not exceed a maximum supply limit of 9 mg/kg/week\n-OR-\n(2) Both of the following:\na. Diagnosis of juvenile-onset hypophosphatasia\nb. Request does not exceed a maximum supply limit of 6 mg/kg/week\n-AND-\ne. One ",
    "d a maximum supply limit of 9 mg/kg/week\n-OR-\n(2) Both of the following:\na. Diagnosis of juvenile-onset hypophosphatasia\nb. Request does not exceed a maximum supply limit of 6 mg/kg/week\n-AND-\ne. One of the following:\n(1) Patient is prescribed Strensiq 18 mg/0.45 mL, Strensiq 28 mg/0.7 mL, or\nStrensiq 40 mg/mL vials\n-OR-\n(2) Both of the following:\na. Patient is prescribed Strensiq 80 mg/0.8 mL vials\n© 2024 UnitedHealthcare Services, Inc.\n3\nb. Patient’s weight is greater than or equal to 40 kg\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Strensiq [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; July 2024.\n2. Choida V, Bubbear JS. Update on the management of hypophosphatasia. Ther Adv\nMusculoskelet Dis. 2019;11:1759720X19863997.\nUpdate on the management of hypophosphatasia - PMC (nih.gov)\n3. Michigami T, Ohata Y, Fujiwara M, et al. Clinical Practice Guidelines for Hypophosphatasia.\nClin Pediatr Endocrinol. 2020;29(1):9-24.\nClinical Practice Guidelines for Hypophosphatasia* - PMC (nih.gov)\n4. Bangura A, Wright L, Shuler T. Hypophosphatasia: Current Literature for Pathophysiology,\nClinical Manifestations, Diagnosis, and Treatment. Cureus. 2020;12(6):e8594.\nHypophosphatasia: Current Literature for Pathophysiology, Clinical Manifestations, Diagnosis,\nand Treatment - PMC (nih.gov)\nProgram Prior Authorization/Medical Necessity – Strensiq (asfotase alfa)\nChange Control\n11/2017 New program.\n5/2019 Ann",
    "thophysiology, Clinical Manifestations, Diagnosis,\nand Treatment - PMC (nih.gov)\nProgram Prior Authorization/Medical Necessity – Strensiq (asfotase alfa)\nChange Control\n11/2017 New program.\n5/2019 Annual review. Updated references.\n5/2020 Annual review with no changes to coverage criteria. Updated reference.\n5/2021 Annual review. No changes to coverage criteria. Updated references.\n6/2021 Updated language to coverage of maximum supply limit.\n6/2022 Annual review. Added criterion for clinical response to reauthorization\ncoverage criteria per prescribing information. Updated references.\n6/2023 Annual review with no changes to criteria. Updated references.\n10/2023 Annual review with no changes to criteria except removal of “routine\naudit” language.\n10/2024 Annual review with no changes to clinical coverage criteria. Updated\nreferences.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}